The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options
Open accessAbstract
Mast cell activation disease comprises disorders characterized by accumulation of genetically altered mast cells and/or abnormal release of these cells' mediators, affecting functions in potentially every organ system, often without causing abnormalities in routine laboratory or radiologic testing. In most cases of mast cell activation disease, diagnosis is possible by relatively non-invasive investigation. Effective therapy often consists simply of antihistamines and mast cell membrane-stabilising compounds supplemented with medications targeted at specific symptoms and complications. Mast cell activation disease is now appreciated to likely be considerably prevalent and thus should be considered routinely in the differential diagnosis of patients with chronic multisystem polymorbidity or patients in whom a definitively diagnosed major illness does not well account for the entirety of the patient's presentation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two principal proposals for diagnostic criteria have emerged.”
From Diagnosis of mast cell activation syndrome: a global "consensus-2" (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Alternative diagnostic criteria of MCAS have also been suggested, but these alternative criteria often lack speci fi city and validation.”
From Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review (2021) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Such alternative approaches with less stringent criteria result in an expanding group of individuals being labeled as having MCAS, but who exhibit a wide and nearly unlimited range of symptoms claimed to be attributable to MCA without clear relation to MCs or attributes of anaphylaxis or MCA.”
From Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review (2021) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These criteria are much broader and less speci fi c for MCA or MCAS.”
From Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review (2021) · cites this paper as [32]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the second published initially in early 2011 [8]”
From Diagnosis of mast cell activation syndrome: a global "consensus-2" (2021) · cites this paper as [8]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic criteria and classification of mastocytosis: a consensus proposal
Valent, P., Horny, H.-P., Escribano, L., Longley, B. J., Li, C. Y., Schwartz, L. B., Marone, G., Nuñez, R., Akin, C., Sotlar, K., et al. (2001) · Leukemia Research · doi:10.1016/s0145-2126(01)00038-8 · Cited by 1,108
Valent, P., Akin, C., Escribano, L., Födinger, M., Hartmann, K., Brockow, K., Castells, M., Sperr, W. R., Kluin‐Nelemans, H. C., Hamdy, N. A. T., et al. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01807.x · Cited by 750 · cited 5×
“The traditionally recognized subclass termed systemic mastocytosis (SM) includes disorders characterized by certain pathological immunohistochemical and mutational findings (the WHO criteria; Table 2; [1,2]) which are divided into several subtypes (Table 1).”
BackgroundInfluentialSystemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors
Lim, K.-H., Tefferi, A., Lasho, T. L., Finke, C., Patnaik, M., Butterfield, J. H., McClure, R. F., Li, C.-Y., & Pardanani, A. (2009) · Blood · doi:10.1182/blood-2009-02-205237 · Cited by 588
Brockow, K., Jofer, C., Behrendt, H., & Ring, J. (2008) · Allergy · doi:10.1111/j.1398-9995.2007.01569.x · Cited by 523
Ruëff, F., Przybilla, B., Biló, M. B., Müller, U., Scheipl, F., Aberer, W., Birnbaum, J., Bodzenta-Lukaszyk, A., Bonifazi, F., Bucher, C., et al. (2009) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.08.027 · Cited by 430
Differential release of mast cell mediators and the pathogenesis of inflammation
Theoharides, T. C., Kempuraj, D., Tagen, M., Conti, P., & Kalogeromitros, D. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00519.x · Cited by 425
Bodemer, C., Hermine, O., Palmérini, F., Yang, Y., Grandpeix-Guyodo, C., Leventhal, P. S., Hadj-Rabia, S., Nasca, L., Georgin-Lavialle, S., Cohen-Akenine, A., et al. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.281 · Cited by 397
The Mast Cell in Interstitial Cystitis: Role in Pathophysiology and Pathogenesis
Sant, G. R., Kempuraj, D., Marchand, J. E., & Theoharides, T. C. (2007) · Urology · doi:10.1016/j.urology.2006.08.1109 · Cited by 337
Mast cell activation syndrome: Proposed diagnostic criteria
Akin, C., Valent, P., & Metcalfe, D. D. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.08.035 · Cited by 327
Research works printed but not linked: 2
- Kolck UW: Investigations on the pathogenesis of the systemic mast cell activation syndrome and its impact on heart function. Bonn, University, medical thesis. 2009, URN:nbn:de:hbz:5N-19064, [ http://hss.ulb.uni-bonn.de/2009/1906/1906.htm ]
- Afrin LB: Polycythemia from mast cell activation disorder: lessons from incongruence of symptoms vs. test results. Am J Med Sci. 2011,
Cited by
Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments
Yong, S. J. (2021) · Infectious Diseases · doi:10.1080/23744235.2021.1924397 · Cited by 1,339
“H1 and H2 antihistamines Cromolyn (mast cell stabilizer) Leukotriene antagonists [176,177]”
BackgroundCovid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome
Afrin, L. B., Weinstock, L. B., & Molderings, G. J. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.09.016 · Cited by 314
Rowe, P. C., Underhill, R. A., Friedman, K. J., Gurwitt, A., Medow, M. S., Schwartz, M. S., Speight, N., Stewart, J. M., Vallings, R., & Rowe, K. S. (2017) · Frontiers in Pediatrics · doi:10.3389/fped.2017.00121 · Cited by 204
Mast Cell-Mediated Mechanisms of Nociception
Aich, A., Afrin, L. B., & Gupta, K. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226151 · Cited by 159
Gensemer, C., Burks, R., Kautz, S. A., Judge, D. P., Lavallee, M. E., & Norris, R. A. (2020) · Developmental Dynamics · doi:10.1002/dvdy.220 · Cited by 166
“This leads to abnormal degranulation in the presence of inappropriate stimuli and can potentially impact all organ systems.(167) Histamine, tryptase and chymase are the main chemical mediators released by mast cells that may lead to allergylike symptoms in patients.”
Background
Metadata
- Authors
- Molderings, G. J., Brettner, S., Homann, J., & Afrin, L. B.
- Affiliations
- University Hospital Bonn (DE)
- Medical University of South Carolina (US)
- Corresponding author
- Molderings, Gerhard J
- Venue
- Journal of Hematology & Oncology
- Published
- 2011-03-22
- Volume
- 4
- Issue
- 1
- Pages
- 10-10
- ISSN
- 1756-8722 (ISSN-L)
- PMC
- PMC3069946
- OpenAlex
- W2117188898
- Cited by
- 149
- References
- 54
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 12 · 2023: 9 · 2022: 7 · 2021: 12 · 2020: 10 · 2019: 12 · 2018: 13 · 2017: 12 · 2016: 9 · 2015: 9 · 2014: 7 · 2013: 10 · 2012: 13
- FWCI
- 0.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0 (tdm)
- Locations
- Journal of Hematology & Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Health Sciences › Medicine › Rheumatology › Eosinophilic Disorders and Syndromes
- Health Sciences › Medicine › Surgery › Congenital gastrointestinal and neural anomalies
- Keywords
- mast cell activation disorders, mast cell mediators, antihistamines, differential diagnosis, diagnostic workup, treatment options
- MeSH terms
- Animals, Histamine Antagonists, Humans, Mast Cells, Mastocytosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. https://app.cochat.ai/papers/10.1186/1756-8722-4-10
- The paper
- Molderings, G. J., Brettner, S., Homann, J., & Afrin, L. B. (2011). Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. Journal of Hematology & Oncology. https://doi.org/10.1186/1756-8722-4-10
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
